IVERIC bio, Inc. (ISEE) financial statements (2021 and earlier)

Company profile

Business Address 5 PENN PLAZA
NEW YORK, NY 10001
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:210126131167289297464
Cash and cash equivalents6612613116713422240
Short-term investments144   15575424
Other undisclosed cash, cash equivalents, and short-term investments   00  
Receivables21 1441
Deferred tax assets    0
Other undisclosed current assets5223369
Total current assets:217129133172296306474
Noncurrent Assets
Operating lease, right-of-use asset00
Nontrade receivables 14    
Property, plant and equipment0001332
Long-term investments and receivables     95 
Long-term investments     95 
Deposits noncurrent assets      0
Other noncurrent assets0000000
Deferred tax assets, net   2323
Other undisclosed noncurrent assets   4   
Total noncurrent assets:0244412225
TOTAL ASSETS:217130137176300429498
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1366812129
Other undisclosed accounts payable and accrued liabilities1366812129
Debt 0     
Deferred revenue and credits 773
Other undisclosed current liabilities1277547198
Total current liabilities:25131313663820
Noncurrent Liabilities
Long-term debt and lease obligation0      
Operating lease, liability0 
Liabilities, other than long-term debt    203206206
Deferred revenue and credits 203206206
Other undisclosed noncurrent liabilities(0)  125125125125
Total noncurrent liabilities:0  125328331331
Total liabilities:251313138394369351
Stockholders' equity
Stockholders' equity attributable to parent19211712438(95)60147
Common stock0000000
Additional paid in capital757598546523505466428
Accumulated other comprehensive income (loss)0   (0)(0)(0)
Accumulated deficit(565)(481)(422)(485)(599)(406)(281)
Total stockholders' equity:19211712438(95)60147
TOTAL LIABILITIES AND EQUITY:217130137176300429498

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit:   210515241
Operating expenses(89)(61)(65)(102)(246)(175)(122)
Operating income (loss):(89)(61)(65)108(196)(124)(81)
Nonoperating income (expense)(0)0(0)(0)00(2)
Investment income, nonoperating      (2)
Other nonoperating income (expense)(0)0(0)(0)00 
Income (loss) from continuing operations before equity method investments, income taxes:(89)(61)(65)108(196)(123)(83)
Other undisclosed income from continuing operations before income taxes121272212
Income (loss) from continuing operations before income taxes:(88)(59)62109(194)(123)(80)
Income tax expense (benefit)4015017(18)
Net income (loss) available to common stockholders, diluted:(85)(59)63114(193)(106)(98)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net income (loss):(85)(59)63114(193)(106)(98)
Comprehensive income (loss):(85)(59)63114(193)(106)(98)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent0  00(0)(0)
Comprehensive income (loss), net of tax, attributable to parent:(85)(59)63114(193)(106)(98)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: